Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2003

View Archived Issues

Novel inhibitors of MMP-12 and other metalloproteinases identified at AstraZeneca

Asahi Kasei presents new beta3-adrenoceptor agonists in recent patent

Imidazolinone-based p38 kinase inhibitors in early development at Tanabe Seiyaku

Shionogi describes novel NR1/NR2B-selective NMDA antagonists

Novel antiobesity agents in Bayer development pipeline

New analgesic COX-1 inhibitors prepared and tested by Fujisawa team

Novel MMP, TACE and/or aggrecanase inhibitors and their use reported by BMS scientists

Dual alpha4beta1/alpha4beta7 integrin antagonist profiled at ATS meeting

Potential new asthma therapeutic acts by neutralizing IL-13

Vaccine for specifically neutralizing IL-13 for use in asthma developed at GSK

SD-208 inhibits lung fibrosis induced by TGF-beta1 overexpression in rats

Inhibition of lung inflammation reported for the macrolide Z-104657A in rats

TAS-203 more effective than cilomilast in airways inflammation

Merck discontinues development of two diabetes projects

Launch of Clarinex RediTabs

Multiferon use expanded in Mexico

PTI-901 significantly improves common symptoms of IBS

Phase II efficacy data reported for intranasal apomorphine in FSD

No evidence of carcinogenicity in NexACT rat study

New phase II trial evaluates ISIS-14803 in HCV

Enrollment under way in pivotal Pompe's disease study of Myozyme

Microbially produced antiplatelet agent identified by Japanese group

Estrone derivatives with potent inhibitory activity against steroid sulfatase

IL-9-neutralizing antibody effective in mouse model of asthma

Allos plans NDA submission for RSR-13 for brain metastases from breast cancer

New phase II trial of Triapine and gemcitabine in pancreatic cancer

NCX-4016 does not negatively interact with COX-2 inhibitor in the stomach

Echelon receives NIH grant to further cancer research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...